AR and prostate carcinoma: The data presented in this paper demonstrated that an inherited physiologic driver of prostate cancer mortality, adrenal-permissive HSD3B1 genotype, which has been shown to be associated with poorer clinical outcomes in nonmetastatic HSPC and mHSPC, is potentially pharmacologically reversible with potent AR antagonism.